PharmaZell

What PharmaZell does

PharmaZell is a Germany-headquartered manufacturer of specialty active pharmaceutical ingredients (APIs) and a subsidiary of Axplora Group GmbH. Founded in 1947 and based in Raubling, the company has built a near-eight-decade track record in API production with a particular specialization in controlled substances — APIs subject to narcotics licensing and heightened regulatory oversight. Within Axplora's three-sub-brand platform (PharmaZell, Farmabios, and Novasep CDMO), PharmaZell contributes specialty-API manufacturing capacity and a dedicated regulatory track record for pharmaceutical customers.

The company supplies active pharmaceutical ingredients into the formulations of drug manufacturers globally, with a customer base served through Axplora's commercial infrastructure spanning Europe, India, and the United States. PharmaZell operates on a B2B direct-sales model targeting enterprise pharmaceutical customers; its go-to-market is anchored in regulatory qualifications, drug master files, and long-term supply agreements that create multi-year qualification cycles. Technical capabilities center on classical small-molecule API process chemistry, regulatory-compliant manufacturing, and controlled-substance handling, rather than novel modalities or biologics, which are addressed by sister entity Novasep CDMO (ADCs, HPAPIs) and Farmabios.

Commercial mechanics are not publicly disclosed: pricing is opaque, no SKU-level or contract data is published, and no standalone revenue or ARR figure is reported by PharmaZell or Axplora. Revenue flows from long-cycle API supply contracts and qualification milestones, supported by a parent-group customer base of more than 900 pharma clients and shared manufacturing, procurement, and regulatory infrastructure. PharmaZell has been under EQT ownership since 2007, has executed at least one disclosed acquisition (GEA Pharmaceutical, July 2007), and continues to benefit from ongoing group-level capacity investments in high-growth API categories such as GLP-1 agonists and antibody-drug conjugates.

Name

PharmaZell

Legal name

PharmaZell

Website

https://pharmazell.com

Company type

Private

Founded year

1947

Operating status

Operating

Headcount range

51–100 employees

Short description

PharmaZell is a German specialty manufacturer of active pharmaceutical ingredients (APIs), with a focus on controlled substances, operating as a subsidiary of the Axplora Group and supplying pharmaceutical companies worldwide across Europe, India, and the United States.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

akta.pro secondary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Active pharmaceutical ingredients
• Specialty API manufacturing
• Controlled substance APIs
• Pharmaceutical intermediates
• Narcotic raw materials

Headquarters

HQ city

Raubling

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Core offering

PharmaZell is a German-based pharmaceutical manufacturer that produces Active Pharmaceutical Ingredients (APIs), with a specialization in controlled substances such as narcotics. As a member of the Axplora Group alongside sister companies Farmabios and Novasep CDMO, it supplies APIs to drug developers and pharmaceutical companies globally from production operations in Europe, India, and the United States.

Product overview

PharmaZell operates as one of three sub-brands under the Axplora group (alongside Farmabios and Novasep CDMO), functioning as an Active Pharmaceutical Ingredients supplier. The company offers a products portfolio of specialty APIs and maintains a regulatory track record. As part of Axplora's integrated API manufacturing ecosystem, PharmaZell contributes to the group's mission of delivering sustainable, technologically-advanced API products and services to over 900 customers worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Specialty Active Pharmaceutical Ingredients (Specialty APIs)
• Products Portfolio (Broad API Range)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Direct peers

• Dishman Carbogen Amcis: Dishman Carbogen Amcis (now part of Dishman Group) is an Indian-headquartered API and intermediates manufacturer with global reach. It is comparable to PharmaZell as a specialty API manufacturer serving pharmaceutical customers across geographies.
• Hovione: Hovione is a privately held CDMO specializing in complex small-molecule APIs and drug substance development. It overlaps with PharmaZell's specialty API manufacturing and shares a similar European base serving global pharma customers.
• Siegfried Holding: Siegfried is a Swiss-listed contract manufacturer of APIs (including controlled substances/narcotics) and finished dosage forms. Its API division is directly comparable to PharmaZell in scope, scale, and regulatory positioning.
• Olon: Olon is a leading Italian CDMO of APIs and intermediates with a strong position in generics and fermentation-derived APIs. It is comparable to PharmaZell as a European-headquartered API manufacturer serving pharmaceutical customers.
• Cambrex: Cambrex is a global contract manufacturer of small-molecule APIs and intermediates, including controlled substances. It is one of the most direct comparables to PharmaZell's specialty API manufacturing business, with similar regulatory positioning and customer base of pharmaceutical companies.
• EuroAPI: EuroAPI is a European API manufacturer (spun out of Sanofi) producing active ingredients including specialty and complex small molecules. It is a direct peer in the European specialty API market where PharmaZell competes.

Emerging players

• Alcami Corporation: Alcami is a US-headquartered CDMO offering API development and manufacturing services for small molecules. It is an emerging player in the specialty API space with overlapping customer segments to PharmaZell, though at a smaller scale.

Broad incumbents

• Lonza: Lonza is a global CDMO leader in small-molecule APIs and biologics, with extensive manufacturing capacity across Europe, the US, and Asia. It serves a similar pharma customer base as PharmaZell, though at much larger scale and broader scope.
• Johnson Matthey Health: Johnson Matthey operates a large API and fine chemicals business (now branded as a standalone entity) with global manufacturing footprint. It is a broader incumbent in specialty API manufacturing, overlapping with PharmaZell but at significantly larger scale.

Regional players

• Divis Laboratories: Divis Laboratories is an Indian API manufacturer focused on generic APIs, intermediates, and nutraceuticals. While it is a strong API competitor, it is primarily based in India and competes with the Axplora/PharmaZell network from a different geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaZell